Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $24.43 Consensus Price Target from Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $24.4286.

DAWN has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Day One Biopharmaceuticals in a report on Monday, November 24th. Piper Sandler upped their price target on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. JPMorgan Chase & Co. raised their price objective on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Zacks Research upgraded shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research report on Monday.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Adam Dubow sold 4,319 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $8.91, for a total transaction of $38,482.29. Following the transaction, the insider owned 62,626 shares of the company’s stock, valued at approximately $557,997.66. This trade represents a 6.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jeremy Bender sold 15,894 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $8.91, for a total value of $141,615.54. Following the completion of the sale, the chief executive officer directly owned 177,165 shares of the company’s stock, valued at approximately $1,578,540.15. This trade represents a 8.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 28,001 shares of company stock worth $249,489. Insiders own 6.20% of the company’s stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of hedge funds have recently modified their holdings of DAWN. Schroder Investment Management Group acquired a new position in Day One Biopharmaceuticals during the 2nd quarter worth approximately $1,171,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Day One Biopharmaceuticals in the first quarter valued at approximately $384,000. Ieq Capital LLC purchased a new stake in shares of Day One Biopharmaceuticals in the first quarter valued at approximately $294,000. Parkman Healthcare Partners LLC grew its holdings in Day One Biopharmaceuticals by 4.3% during the first quarter. Parkman Healthcare Partners LLC now owns 1,043,162 shares of the company’s stock worth $8,272,000 after acquiring an additional 42,688 shares during the period. Finally, Geode Capital Management LLC raised its position in Day One Biopharmaceuticals by 11.2% in the second quarter. Geode Capital Management LLC now owns 1,712,429 shares of the company’s stock worth $11,132,000 after acquiring an additional 171,964 shares in the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Trading Up 3.2%

Shares of NASDAQ:DAWN opened at $8.51 on Monday. The company has a market cap of $873.81 million, a PE ratio of -5.60 and a beta of -1.27. The company’s 50 day moving average is $8.19 and its two-hundred day moving average is $7.29. Day One Biopharmaceuticals has a 52 week low of $5.64 and a 52 week high of $13.53.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.09. Day One Biopharmaceuticals had a negative return on equity of 32.05% and a negative net margin of 113.53%.The firm had revenue of $39.80 million for the quarter, compared to analyst estimates of $38.20 million. During the same quarter in the prior year, the company posted $0.38 earnings per share. Day One Biopharmaceuticals’s revenue for the quarter was down 57.6% compared to the same quarter last year. As a group, equities research analysts expect that Day One Biopharmaceuticals will post -0.72 EPS for the current year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.